
Business Of Biotech
Ben ComerAudio
- Format:
- Podcast
- New episodes:
- Weekly
- Typical length:
- about 55 minutes
- Latest episode:
About this show
The Business of Biotech is the pod dedicated to leaders of emerging biopharma firms. SUBSCRIBE to our new newsletter at www.bioprocessonline.com/bob. We bring you insight into organizational, finance and funding, HR, clinical, manufacturing, regulatory, and commercial challenges you’ll face as you navigate your company from an idea to success in the clinic and beyond. Each episode features guest commentary and best practices from accomplished founders and biopharma industry luminaries. The Business of Biotech is produced by Life Science Connect.
Covers: biotech, biopharmaceuticals, biotech investing, drug development, biotech finance, clinical trials, oncology, manufacturing, startup leadership, venture capital
Show details and episodes come from the publisher's public feed at rss.buzzsprout.com. Last updated . Names, artwork and text belong to their publishers.
Recently on this show
Summary of recent episodes, drawn from the publisher's feed.
This podcast features founders and industry leaders from emerging biopharma firms, examining organizational, funding, clinical, manufacturing, regulatory, and commercial challenges. Recent episodes cover launching an oncology product, managing a neuroscience portfolio, bioprinting human tissue models, and AI and China in biotech investing.
Cosmos
Similar in subject
- The Biotech Startups Podcast
Both cover: biotech, drug development, clinical trials - Biotech Hangout
Both cover: biotech investing, biotech, clinical trials - BioSpace
Both cover: oncology, drug development, clinical trials
Similar shows
Explore more
Episodes
Targeting Tau in Alzheimer's Disease With Voyager Therapeutics' Al Sandrock, M.D., Ph.D.
· 48 min
We love to hear from our listeners. Send us a message. (https://www.buzzsprout.com/1011661/fan_mail/new) On this week's episode of the Business of Biotech, Al Sandrock, M.D., Ph.D., President and CEO at Voyager Therapeutics, talks about why tau is becoming a central target in Alzheimer’s drug development and how gene therapy delivery across the blood-brain barrier could change what treatment looks like at scale. Sandrock shares his current thinking on the amyloid vs. beta debate (it's likely both) in Alzheimer's disease treatment, the role of emerging tools like fluid biomarkers in diagnosis and prevention, and why small biotechs take bigger risks than big pharma. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech (https://www.lifescienceleader.com/solution/the-business-of-biotech-podcast-lsl) tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter (https://www9.lifescienceleader.com/business-of-biotech-nl-sign-up/). Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
Not rated yetKeeping An Early-Stage Cell Therapy Biotech In The Black With IN8bio's William Ho
· 55 min
We love to hear from our listeners. Send us a message. (https://www.buzzsprout.com/1011661/fan_mail/new) On this week's episode of the Business of Biotech, William Ho, CEO of IN8bio, explains why gamma delta T cells may have an edge against cancer, including solid tumors like glioblastoma. He also offers up a candid and step-by-step look at what it takes to finance an early clinical-stage cell therapy company through a punishing IPO market and a long cash crunch. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech (https://www.lifescienceleader.com/solution/the-business-of-biotech-podcast-lsl) tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter (https://www9.lifescienceleader.com/business-of-biotech-nl-sign-up/). Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
Not rated yetDrug Launch Success In A Changing Commercial Landscape With ACMA's William Soliman, Ph.D.
· 55 min
We love to hear from our listeners. Send us a message. (https://www.buzzsprout.com/1011661/fan_mail/new) On this week's episode of the Business of Biotech, William Soliman, Founder and CEO of the Accreditation Council for Medical Affairs (ACMA), and Founder and CIO of White Manna Capital Partners, talks about why biotech drug launches so often miss expectations, and how to build an integrated commercialization plan that holds up with physicians, patients, and payers. William also describes the evolution in medical affairs, why standards and certification matter, and how AI and new media channels are reshaping how drug information reaches patients and prescribers. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech (https://www.lifescienceleader.com/solution/the-business-of-biotech-podcast-lsl) tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter (https://www9.lifescienceleader.com/business-of-biotech-nl-sign-up/). Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
Not rated yetThe Editors' Roundtable: A Midyear Look At The 2026 Life Sciences Industry
· 1 hr 24 min
We love to hear from our listeners. Send us a message. (https://www.buzzsprout.com/1011661/fan_mail/new) On this week's episode of the Business of Biotech, Tyler Menichiello, chief editor at Bioprocess Online, host of the Better Biopharma podcast, and my Life Science Connect (LSC) colleague, convenes the broader LSC editorial team once again for a midyear discussion on what's happening now in the life sciences industry, and what's to come in the second half of the year. Topics include AI manufacturing regulations and navigating supply chain pressures, outsourcing trends and onshoring, biotech market signals and IPOs, clinical development's slow shift to digitization, the move toward organoids and non-animal models (NAMs) in discovery, RNA modality growing pains, and more. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech (https://www.lifescienceleader.com/solution/the-business-of-biotech-podcast-lsl) tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter (https://www9.lifescienceleader.com/business-of-biotech-nl-sign-up/). Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
Not rated yetDerisking CNS Drug Development With Tortugas Neuroscience's Jeff Jonas, M.D.
· 49 min
We love to hear from our listeners. Send us a message. (https://www.buzzsprout.com/1011661/fan_mail/new) On this week's episode of the Business of Biotech, Jeff Jonas, M.D., CEO of Tortugas Neuroscience, talks about the company's April 2026 launch and how in-licensed development assets were chosen. Jeff explains his strategy of chasing fast proof of safety and efficacy in humans, not animals, and talks about what product differentiation looks like in brain disorders, from adjusting indication targets to conducting head-to-head trials. He also reflects on the opportunity with psychedelics, RFK Jr.'s quest to curb SSRI prescriptions, the payer landscape in CNS disorders, and more. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech (https://www.lifescienceleader.com/solution/the-business-of-biotech-podcast-lsl) tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter (https://www9.lifescienceleader.com/business-of-biotech-nl-sign-up/). Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
Not rated yetRare Disease Drug Commercialization With Zevra Therapeutics' Neil McFarlane
· 55 min
We love to hear from our listeners. Send us a message. (https://www.buzzsprout.com/1011661/fan_mail/new) On this week's episode of the Business of Biotech, Neil McFarlane, CEO at Zevra Therapeutics, talks about transitioning to a focused rare disease company through acquisitions, and building out a commercial organization. Neil explains the importance of working with rare disease patient advocacy groups, using AI to analyze electronic health records and claims data to identify and diagnose patients with Niemann-Pick disease type C, and adapting to regulatory inconsistencies around rare disease drug approval frameworks in the U.S. and Europe. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech (https://www.lifescienceleader.com/solution/the-business-of-biotech-podcast-lsl) tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter (https://www9.lifescienceleader.com/business-of-biotech-nl-sign-up/). Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
Not rated yetScaling Manufacturing For Personalized Cell Therapies With Cellino's Marinna Madrid, Ph.D.
· 50 min
We love to hear from our listeners. Send us a message. (https://www.buzzsprout.com/1011661/fan_mail/new) On this week's episode of the Business of Biotech, Marinna Madrid, Ph.D., Cofounder, Board Member, Chief Product and Regulatory Officer at Cellino, talks about scaling up an automated manufacturing process she co-invented for personalized autologous induced pluripotent stem cell (iPSC) therapies using laser-activated substrates and AI. Marinna describes her work with industry groups to improve regulatory guidelines, Cellino's partnership strategy, the implications of receiving FDA's Advanced Manufacturing Technologies designation, and the future of iPSC therapies. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech (https://www.lifescienceleader.com/solution/the-business-of-biotech-podcast-lsl) tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter (https://www9.lifescienceleader.com/business-of-biotech-nl-sign-up/). Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
Not rated yetBuilding A New Antibody Discovery Platform With Infinimmune's Wyatt McDonnell, Ph.D.
· 54 min
We love to hear from our listeners. Send us a message. (https://www.buzzsprout.com/1011661/fan_mail/new) On this week's episode of the Business of Biotech, Wyatt McDonnell, Ph.D., cofounder and CEO at Infinimmune, talks about how single-cell biology and computational rigor led to the formation of Infinimmune, and a new way to discover human-derived antibody drugs. Wyatt explains Infinimmune's 'discovered in humans' antibody discovery platform, how the company was launched and initially funded, and how Infinimmune landed a Merck collaboration worth up to $838 million. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech (https://www.lifescienceleader.com/solution/the-business-of-biotech-podcast-lsl) tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter (https://www9.lifescienceleader.com/business-of-biotech-nl-sign-up/). Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
Not rated yetFrom Partnered ASO Therapies To A Wholly-Owned Pipeline With Ionis's Brett Monia, Ph.D.
· 55 min
We love to hear from our listeners. Send us a message. (https://www.buzzsprout.com/1011661/fan_mail/new) On this week's episode of the Business of Biotech, Brett Monia, Ph.D., CEO at Ionis Pharmaceuticals, talks about how antisense oligonucleotides (ASO) graduated from a late-1980s lab concept to real RNA-targeting medicines, and why Ionis stuck with a difficult modality despite multiple setbacks. Brett describes the company's shift from a partner-first model to building a wholly-owned pipeline, commercial function, and an expanded manufacturing operation, and how he as a founding scientist-turned-CEO bridged a skills gap in finance and investor relations. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech (https://www.lifescienceleader.com/solution/the-business-of-biotech-podcast-lsl) tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter (https://www9.lifescienceleader.com/business-of-biotech-nl-sign-up/). Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
Not rated yetImplementing A New CEO Strategy With NervGen's Adam Rogers, M.D. And Rich Macary
· 47 min
We love to hear from our listeners. Send us a message. (https://www.buzzsprout.com/1011661/fan_mail/new) On this week's episode of the Business of Biotech, we talk with NervGen leaders Adam Rogers, M.D., and Rich Macary about NVG-291, a daily neuroreparative peptide designed to restore function in patients with spinal cord injuries. Adam talks about his strategy for the company after becoming CEO last July, including moving company trading from Canada's TSX Venture Exchange to the NASDAQ for better visibility, and making key hires for growth. Rich talks about his early work in RNA therapeutics as an advisor at Sarepta, cofounding Synaptica Therapeutics, and bringing Adam to NervGen. They also talk about engaging with the FDA on endpoints for NVG-291's Phase 3 trial, and the broader opportunity in neurotrauma. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech (https://www.lifescienceleader.com/solution/the-business-of-biotech-podcast-lsl) tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter (https://www9.lifescienceleader.com/business-of-biotech-nl-sign-up/). Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
Not rated yetThe Impact Of FDA Risk On Biotech Rewards With CFO And Board Director Allan Shaw
· 46 min
We love to hear from our listeners. Send us a message. (https://www.buzzsprout.com/1011661/fan_mail/new) On this week's episode of the Business of Biotech, five-time public company CFO and seven-time public company board member Allan Shaw talks about why FDA decision-making feels less predictable, and how that uncertainty is reshaping clinical trial strategy, investor behavior, and the innovation ecosystem. We talk about FDA politicization concerns, modernization efforts like AI initiatives, and what biotech leaders can do to manage risk instead of being managed by it. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech (https://www.lifescienceleader.com/solution/the-business-of-biotech-podcast-lsl) tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter (https://www9.lifescienceleader.com/business-of-biotech-nl-sign-up/). Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
Not rated yetBiosimilars And Complex Medicines For All With RNA Therapeutics' Sarfaraz Niazi, Ph.D.
· 58 min
We love to hear from our listeners. Send us a message. (https://www.buzzsprout.com/1011661/fan_mail/new) On this week's episode of the Business of Biotech, we speak with Dr. Sarfaraz Niazi, Ph.D., about how biosimilar regulations have taken shape, from early FDA uncertainty to citizen petitions, lawsuits, and guideline changes. Dr. Niazi offers a behind the scene look at the way FDA policy gets made, and unmade, and his own role in key regulatory changes, and legislation such as the Biologics Price Competition and Innovations Act (BPCIA), and the Inflation Reduction Act (IRA). We also discuss Dr. Niazi's current company, RNA Therapeutics, and his quest to make new drug modalities accessible to patients around the world. This episode of the Business of Biotech is brought to you by Cytiva. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech (https://www.lifescienceleader.com/solution/the-business-of-biotech-podcast-lsl) tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter (https://www9.lifescienceleader.com/business-of-biotech-nl-sign-up/). Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
Not rated yetRadiotherapeutics For Neuroendocrine Tumors With Perspective Therapeutics' Thijs Spoor
· 40 min
We love to hear from our listeners. Send us a message. (https://www.buzzsprout.com/1011661/fan_mail/new) On this week's episode of the Business of Biotech, Thijs Spoor, CEO at Perspective Therapeutics, a company developing Pb 212 (lead)-based therapeutics, talks about why radiopharmaceuticals are surging again and why biodistribution is the make-or-break variable when your payload is a radioactive isotope. Thijs discusses the reasons behind Perspective's investment in a proprietary generator for therapeutic production, manufacturing and delivery strategy, workforce constraints, and building a clinical strategy around receptor positivity across tumor types. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech (https://www.lifescienceleader.com/solution/the-business-of-biotech-podcast-lsl) tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter (https://www9.lifescienceleader.com/business-of-biotech-nl-sign-up/). Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
Not rated yetInvesting In Early-Stage Oncology With Yosemite's Dan McHugh
· 55 min
We love to hear from our listeners. Send us a message. (https://www.buzzsprout.com/1011661/fan_mail/new) On this week's episode of the Business of Biotech, Dan McHugh, head of the investment team at Yosemite, explains the San Francisco VC group's approach to investing in early-stage cancer therapeutics and funding academic research through unrestricted grants. Founded by Reed Jobs, son of Steve Jobs and Laurene Powell Jobs, Yosemite invests across drug modalities and supporting technologies in the oncology space. Dan talks about his path from bioengineering to biotech venture capital, meeting Reed Jobs on Stanford's fencing team, his CEO turn at Tune Therapeutics, and the current fundraising environment for innovative science. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech (https://www.lifescienceleader.com/solution/the-business-of-biotech-podcast-lsl) tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter (https://www9.lifescienceleader.com/business-of-biotech-nl-sign-up/). Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
Not rated yetCommercializing CAR T Cell Therapy With Legend Biotech's Alan Bash
· 50 min
We love to hear from our listeners. Send us a message. (https://www.buzzsprout.com/1011661/fan_mail/new) On this week's episode of the Business of Biotech we're speaking with Alan Bash, President, Carvykti, at Legend Biotech, about how Carvykti became a blockbuster, category-leading CAR T therapy for multiple myeloma. Alan talks about manufacturing and delivering an autologous cell therapy at commercial scale, Legend Biotech's partnership with Johnson & Johnson, lessons he learned at Bristol Myers Squibb, Checkmate Pharmaceuticals, and ZielBio, and his strategy for growing Carvykti's patient footprint and facing new competitors in the market. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech (https://www.lifescienceleader.com/solution/the-business-of-biotech-podcast-lsl) tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter (https://www9.lifescienceleader.com/business-of-biotech-nl-sign-up/). Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
Not rated yetRadiotherapeutics For CNS Cancers With Plus Therapeutics' Marc Hedrick, M.D.
· 54 min
We love to hear from our listeners. Send us a message. (https://www.buzzsprout.com/1011661/fan_mail/new) On this week's episode of the Business of Biotech we speak with Dr. Marc Hedrick, M.D., President and CEO at Plus Therapeutics, about the company's pivot from cell therapy to radiotherapeutics for brain cancers, and what's behind the choice of Rhenium-186 as the radioisotope for its lead development candidate, Reyobiq. We'll talk about Plus Therapeutics' diagnostic subsidiary, CNSide, and hear from Marc about recent FDA meetings and the agency's attitude toward novel radiotherapeutics. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech (https://www.lifescienceleader.com/solution/the-business-of-biotech-podcast-lsl) tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter (https://www9.lifescienceleader.com/business-of-biotech-nl-sign-up/). Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
Not rated yetDeveloping Novel Cancer Drugs On A Budget With Iterion Therapeutics' Rahul Aras, Ph.D.
· 48 min
We love to hear from our listeners. Send us a message. (https://www.buzzsprout.com/1011661/fan_mail/new) On this week's episode of the Business of Biotech we speak with Rahul Aras, Ph.D., President and CEO at Iterion Therapeutics, about capital efficient drug development in oncology and progressing a novel therapeutic with relatively small funding amounts. Iterion is a clinical stage company developing cancer therapeutics targeting the Wnt/β-catenin pathway, a known signaling target in oncology, but one that has confounded drug development efforts for decades. Rahul talks about his path from academia to company building and early work in gene therapy, Iterion's partnership strategy, and operating a biotech in the Houston, Texas clinical hub. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech (https://www.lifescienceleader.com/solution/the-business-of-biotech-podcast-lsl) tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter (https://www9.lifescienceleader.com/business-of-biotech-nl-sign-up/). Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
Not rated yetMaking Biologics Orally Available With Vivtex's Thomas von Erlach, Ph.D.
· 53 min
We love to hear from our listeners. Send us a message. (https://www.buzzsprout.com/1011661/fan_mail/new) On this week's episode of the Business of Biotech, we're speaking with Thomas von Erlach, Ph.D., Cofounder and CEO at Vivtex, a company spun out of the Langer Lab at MIT that's focused on developing orally available biologics. The company announced a deal in late February '26 with Novo Nordisk for up to $2.1 billion to develop next-gen oral drugs for obesity and diabetes, bringing the total number of Vivtex's partnerships to 10. Thomas shares his experiences working in the lab with Dr. Robert Langer, Ph.D., starting up Vivtex around his co-invention (a "GI tract on a chip"), building trust externally and securing the right partnerships, and using a strategic stealth period to refine Vivtex's platform technology before scaling it out. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech (https://www.lifescienceleader.com/solution/the-business-of-biotech-podcast-lsl) tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter (https://www9.lifescienceleader.com/business-of-biotech-nl-sign-up/). Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
Not rated yetAn Anthropological Lens On Leadership In Life Sciences With Bunka's Monika Sumra, Ph.D.
· 58 min
We love to hear from our listeners. Send us a message. (https://www.buzzsprout.com/1011661/fan_mail/new) On this week's episode of the Business of Biotech we speak with Monika Sumra, Ph.D., about how leadership, culture, and performance emerge from the environment and conditions inside an organization. Dr. Sumra, Founder and Managing Partner at Bunka, Inc., a management consulting firm and advisor to manufacturing-based organizations globally, explains how anthropology, CPIs, and rapid ethnography make culture measurable and operations faster, safer, and more reliable. Deploying a unique lens built on biosocial anthropology, she offers guidance on creating environments for sustainable performance in the complex life sciences industry. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech (https://www.lifescienceleader.com/solution/the-business-of-biotech-podcast-lsl) tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter (https://www9.lifescienceleader.com/business-of-biotech-nl-sign-up/). Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
Not rated yetCompany Turnarounds And AI For Infectious Diseases With Seek Labs' Jared Bauer
· 56 min
We love to hear from our listeners. Send us a message. (https://www.buzzsprout.com/1011661/fan_mail/new) On this week's episode of the Business of Biotech, Jared Bauer, Cofounder and CEO at Seek Labs, talks about his adventures in company turnarounds, and setting up Seek Labs to improve patient diagnoses and to discover and develop new treatments for infectious diseases. Jared explains the technology convergence that was needed to build Seek Labs' AI diagnostic and CRISPR-based therapeutics platform, an African Swine Fever proof-of-concept study that reduced viremia in pigs, mapping pathogens for rapid target design, and engaging with the FDA and global regulatory agencies. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech (https://www.lifescienceleader.com/solution/the-business-of-biotech-podcast-lsl) tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter (https://www9.lifescienceleader.com/business-of-biotech-nl-sign-up/). Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
Not rated yet